Home Hematologic Cancer Markers ClonoSEQ Test: MRD Monitoring in Leukemia, Lymphoma, Myeloma, and Result Meaning

ClonoSEQ Test: MRD Monitoring in Leukemia, Lymphoma, Myeloma, and Result Meaning

By
Vita Library
-
1
Learn how the ClonoSEQ MRD test tracks residual leukemia, lymphoma, and myeloma, what positive or undetectable results mean, and why sample sensitivity matters.

The ClonoSEQ test is a next-generation sequencing test that can detect and measure very small numbers of blood cancer cells left after treatment, called measurable residual disease or MRD. Instead of looking broadly for abnormal cells, ClonoSEQ first identifies a unique immunoglobulin or T-cell receptor DNA sequence from the cancer clone and then searches for that same sequence in later samples. With enough high-quality DNA, the assay can reach a sensitivity around one cancer-associated sequence among one million cell equivalents, although the actual limit for an individual specimen depends on how much usable material is tested. ClonoSEQ is used most clearly in multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available in selected other lymphoid cancers under laboratory-developed testing. A positive result means the tracked clone was detected. A negative result means it was not detected down to the stated sensitivity of that sample—not that every cancer cell in the body is gone. Timing, specimen type, disease, and treatment context are essential to interpretation.

  • ClonoSEQ is an NGS-based MRD test that tracks a cancer clone’s unique immune-receptor DNA sequence. It is different from routine mutation panels or whole-genome sequencing.
  • A positive result means the tracked clonotype was detected in that specimen. The report may quantify the level and show how it changed from prior tests.
  • An undetectable result is limited by sample sensitivity. “Not detected” at 10^-6 is more sensitive than “not detected” at 10^-4, but neither proves zero disease anywhere in the body.
  • ClonoSEQ can reach about 10^-6 sensitivity when enough suitable DNA is available. Low cell counts, poor sample quality, and patchy marrow disease can reduce the effective sensitivity.
  • MRD results should guide care only in a disease-specific plan. A single result usually should not trigger starting, stopping, or changing treatment without considering the clinical setting and other tests.

Table of Contents

What ClonoSEQ Measures

ClonoSEQ measures residual cancer by tracking a clonotype—a distinctive rearranged DNA sequence made by the malignant B cell, plasma cell, or T cell. B and T cells naturally rearrange immunoglobulin or T-cell receptor genes as they mature. A cancer that grows from one lymphoid cell usually carries copies of the same rearranged sequence, creating a molecular fingerprint that can be followed over time.

The test uses multiplex polymerase chain reaction followed by next-generation sequencing. Depending on the disease and specimen, the assay can identify rearrangements involving immunoglobulin heavy, kappa, or lambda genes and T-cell receptor genes, as well as certain rearrangements used for clonality assessment. It is therefore a clonality and MRD assay, not a test for every cancer mutation.

That distinction matters. A leukemia mutation panel may look for genes such as TP53, FLT3, or NOTCH1. ClonoSEQ instead asks a different question: Can the previously identified cancer clone still be found, and at what level? This makes it closely related to other leukemia MRD methods, but the molecular target and workflow are different.

MRD is called “measurable” rather than “minimal” residual disease because modern assays can quantify very low disease levels. A patient may look to be in complete remission by routine blood counts, imaging, or standard microscopy while an MRD assay still detects one malignant cell equivalent among tens of thousands or hundreds of thousands of normal cells.

The practical value is that deeper remissions often correlate with a lower relapse risk at the group level. The meaning of a specific MRD level, however, varies by disease, treatment, time point, and specimen. ClonoSEQ provides a measurement; the hematology team supplies the clinical interpretation.

How ClonoSEQ Testing Works

ClonoSEQ usually works in two stages: first identify the tumor-specific clonotype, then track that same sequence in later samples. The identification step is most successful when the specimen contains enough untreated or clearly detectable disease.

A diagnostic bone marrow, blood sample, or archived tissue may be used to establish the clonotype depending on the malignancy. Once one or more trackable sequences are found, later samples can be compared with that baseline. This is why saving or testing diagnostic material can be valuable even when MRD testing will not occur until months later.

The tracking sample is processed to extract DNA, amplify the relevant immune-receptor regions, sequence many DNA molecules, and count copies that match the original clone. The report also estimates how many cell equivalents were evaluated. That number helps determine the limit of detection, which is the lowest level at which the laboratory can reliably detect the clonotype in that particular specimen.

A commonly discussed sensitivity is 10^-6, meaning about one cancer-associated sequence among one million cell equivalents. Reaching that depth requires enough amplifiable DNA. A smaller or diluted sample may only support 10^-4 or 10^-5 sensitivity. Therefore, two reports that both say “not detected” may not be equivalent if one tested far more cellular material.

Baseline identification can be a critical step

If no suitable clonotype is identified at baseline, later sequence-based tracking may not be possible or may be less straightforward. This problem can occur when the specimen has very little disease, degraded DNA, unusual rearrangements, or insufficient material. In multiple myeloma, for example, marrow involvement may be patchy, and a dilute aspirate can reduce the amount of tumor DNA available for identification.

For U.S. clinical use, ClonoSEQ is currently FDA-cleared for MRD detection in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia and in blood or bone marrow from patients with CLL. Other lymphoid cancers and specimen types may be offered as CLIA-validated laboratory-developed testing. Regulatory status and coverage can change, so clinicians use the current laboratory indication for the exact disease and specimen rather than assuming all ClonoSEQ applications are equivalent.

How to Read ClonoSEQ Results

The most important parts of a ClonoSEQ report are whether the tracked clonotype was detected, the estimated disease level, and the sensitivity achieved in that sample. A positive or detectable result means the assay found the known cancer-associated sequence. An undetectable result means it did not find that sequence down to the test’s stated limit.

Report elementWhat it meansWhat it does not mean
Detected / MRD positiveThe tracked clonotype was found in the tested specimenIt does not automatically mean clinical relapse or immediate treatment is required
Not detected / MRD undetectableThe clonotype was not found to the achieved assay sensitivityIt does not prove that no cancer cells exist anywhere in the body
10^-4About 1 tracked cell equivalent per 10,000 cell equivalentsIt is not the same depth as 10^-6
10^-6About 1 tracked cell equivalent per 1,000,000 cell equivalentsIt is achievable only when sufficient high-quality input is available
Rising serial levelMore tracked sequence is being measured over timeIt still requires disease-specific clinical interpretation

The terms MRD4, MRD5, and MRD6 are sometimes used to describe thresholds of 10^-4, 10^-5, and 10^-6. In CLL, “uMRD4” commonly means disease is undetectable below 10^-4 under the defined method and specimen. In myeloma, very deep NGS thresholds such as 10^-5 and 10^-6 are often emphasized. The exact reporting language varies, so the number and the assay sensitivity are more informative than the word “negative” alone.

A result can also be positive below the formal limit of quantitation. That can mean the sequence was detected but there were too few copies for precise numerical measurement. Such a result should not be treated as identical to a robustly quantified MRD level.

Trend matters. A stable low level after therapy, a steadily falling level, and a repeatedly rising level are different clinical patterns. Yet serial changes should be interpreted using comparable specimens and time points whenever possible. Switching from marrow to blood can change the apparent level because some diseases are more readily detected in one compartment than another.

ClonoSEQ in Leukemia

ClonoSEQ has its clearest leukemia roles in B-cell acute lymphoblastic leukemia and CLL, where molecular MRD can detect disease far below the level visible on routine microscopy. The implications differ between the two diseases.

In B-ALL, MRD after induction or consolidation is a major response measure. Persistent molecular disease can identify a higher-risk group even when the marrow looks morphologically clear. Very sensitive NGS can sometimes detect residual clonotypes below the threshold of standard flow cytometry or conventional PCR. The significance depends on the treatment protocol, age group, genetic subtype, transplant plan, and exact sampling time.

An MRD-positive result after therapy does not by itself define what the next treatment must be. Some protocols use MRD to intensify therapy, choose immunotherapy, or guide transplant decisions, but those actions follow disease-specific guidelines. A result that is clinically decisive at one time point may be less important at another.

In CLL, MRD is especially useful after fixed-duration treatments designed to produce deep remissions. Blood is convenient and informative, but marrow can be more sensitive in some situations. A patient can be undetectable in peripheral blood while low-level disease remains in bone marrow. This is why reports should always identify the specimen type.

MRD is different from stable baseline risk markers. For example, the CLL IGHV mutation test describes the biological background of the leukemia and generally does not change over time; ClonoSEQ measures how much of a tracked clone remains after treatment. One helps characterize the disease, while the other measures response.

For acute myeloid leukemia, MRD is important but is generally assessed with other molecular targets and/or flow cytometry because AML does not usually provide the same immunoglobulin or T-cell receptor clonotype framework used by ClonoSEQ. “Leukemia MRD” is therefore not one universal test.

ClonoSEQ in Multiple Myeloma

In multiple myeloma, ClonoSEQ can measure deep bone marrow MRD after treatment and is often interpreted alongside marrow morphology, flow cytometry, blood monoclonal-protein tests, and imaging. Achieving MRD negativity is strongly associated with better progression-free outcomes across groups of patients, but it is not a guarantee of cure.

Myeloma creates a special sampling problem because plasma cells can be distributed unevenly through the marrow. A single aspirate may miss a focal pocket of disease. The first pull of a marrow aspirate is often preferred for MRD because later pulls can be diluted with peripheral blood. Even a technically excellent 10^-6 result describes the tested marrow sample, not every bone or soft-tissue site in the body.

This is why modern myeloma response assessment may combine molecular MRD with functional imaging. A patient can be marrow MRD negative yet still have an active focal lesion on PET/CT or another imaging study. Conversely, a treated lesion may remain structurally visible while no longer containing active tumor. Multimodal assessment gives a more complete picture.

ClonoSEQ does not replace the multiple myeloma test panel used for routine follow-up. Serum protein electrophoresis, immunofixation, free light chains, blood counts, kidney function, calcium, and imaging answer different questions and are usually easier to repeat than a marrow biopsy.

Recent studies have explored whether sustained deep MRD negativity can help identify patients who may safely reduce or stop maintenance therapy. These data are promising, including studies using ClonoSEQ at 10^-6 or deeper experimental thresholds, but they do not create a universal rule that one negative test means maintenance should end. Duration of negativity, disease risk, prior treatment, imaging, side effects, and patient preferences all matter.

A useful question after a myeloma ClonoSEQ result is not simply “Is it negative?” but “At what sensitivity, in what specimen, after which treatment, and has the result stayed negative over time?”

ClonoSEQ in Lymphoma

ClonoSEQ can track clonotypes in selected lymphomas, but lymphoma MRD use is less uniform than in the FDA-cleared marrow and blood indications for myeloma, B-ALL, and CLL. The useful specimen may be tissue, blood, marrow, or circulating tumor DNA-containing plasma depending on the lymphoma and testing program.

A lymphoma must first have a trackable rearrangement. B-cell lymphomas often carry clonal immunoglobulin sequences, while T-cell lymphomas can carry clonal T-cell receptor sequences. Identification may use diagnostic tissue because many lymphomas have little or no circulating disease in blood.

Research in follicular lymphoma has shown that persistent molecular undetectability at deep thresholds can correlate with durable remissions. Other studies have explored clonotype sequencing in mantle cell lymphoma, diffuse large B-cell lymphoma, and cutaneous T-cell lymphoma. However, the evidence, accepted thresholds, specimen types, and treatment decisions are not standardized across all lymphoma subtypes.

This means “ClonoSEQ negative” in lymphoma should never be interpreted without the disease name and testing context. A negative blood test may be reassuring in a lymphoma that routinely sheds tumor DNA into blood but less informative for disease confined to a lymph node or extranodal site. Imaging and clinical examination can remain central even when molecular testing is available.

Flow cytometry also plays a different role across lymphoma types. A lymphoma flow cytometry panel helps identify and classify abnormal lymphoid populations in suitable fresh specimens, while clonotype NGS is designed to find a known molecular signature at very low abundance. The tests can be complementary rather than interchangeable.

Limitations, Timing, and Next Steps

The biggest limitation of ClonoSEQ is that an MRD number is only as meaningful as the specimen, sensitivity, baseline clonotype, and clinical time point behind it. Deep sequencing is highly sensitive, but it cannot correct for a sample that does not contain the disease compartment being sought.

Common limitations include:

  • no trackable clonotype identified from the baseline specimen;
  • too little DNA or too few cells to reach the desired sensitivity;
  • hemodiluted or patchy bone marrow sampling;
  • disease located outside the sampled marrow or blood compartment;
  • differences between blood and marrow disease levels;
  • very low positive signals that are detectable but difficult to quantify precisely; and
  • uncertain treatment implications in diseases or time points where MRD-guided decisions are still being studied.

MRD testing is most useful when planned before the sample is collected. The hematology team can choose the right specimen, time it relative to therapy, and make sure baseline material exists. Repeating the test too frequently without a clinical question can create anxiety around small fluctuations that may not change management.

When reviewing a report, ask: Was a baseline sequence successfully identified? What specimen was tested? How many cell equivalents were analyzed? What sensitivity was achieved? Was disease detected below the quantifiable range? Is this result being compared with prior tests from the same compartment? Most importantly, what decision—if any—would change because of the result?

MRD should be interpreted with the rest of the response assessment. For myeloma that may include monoclonal protein studies and imaging; for CLL it may include blood counts, examination, imaging when indicated, and molecular risk markers; for ALL it may include marrow morphology, flow cytometry, and protocol-specific molecular tests. Discordant results are not automatically errors because different methods sample different biological signals.

A newly positive ClonoSEQ result after prior undetectable tests does not always equal clinical relapse. It can precede conventional relapse, but the importance depends on the level, trend, disease, treatment, and protocol. Conversely, an undetectable result should not be used as permission to stop prescribed therapy unless the treating team is following evidence or a protocol that supports that decision.

For patients, the most useful way to think about ClonoSEQ is as a high-resolution ruler. It can measure disease far below ordinary detection limits, but the number still needs a map: the cancer type, body compartment, treatment history, and validated decision rules. That context turns a technically sensitive result into clinically useful information.

References

Disclaimer

This article is for general education and does not diagnose cancer or recommend starting, stopping, or changing treatment. ClonoSEQ results must be interpreted by the treating hematology team using the cancer type, specimen, achieved sensitivity, treatment time point, and other response tests. Seek urgent medical care for severe bleeding, high fever, breathing difficulty, confusion, or other rapidly worsening symptoms.

RELATED ARTICLESMORE FROM AUTHOR